Showing 2211-2220 of 7783 results for "".
Dr. Chan Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-chan-discusses-experience-with-gemini-laser/19471/“Gemini is an extremely effective non-ablative skin rejuvenation laser. And by combining the 532 KTP lasers with the long pulse 1064 YAG, we can achieve non-ablative skin rejuvenations in terms of reductions of pigmentations, fine lines, pore size and vessel improvement.” & #8212Professor HenrySclerotherapy - Part 3
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/sclerotherapy-part-3/19500/This is the third video in a series of four.BodyJet Infiltration
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bodyjet_meyer-infiltration/19520/Demonstration of cannula placement in the anterior and posterior thigh.The Battle of Biostimulators: PLLA vs Hyperdilute CaHA
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/the-battle-of-biostimulators-plla-vs-hyperdilute-caha/39250/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, hosts a workshop describing the differences between two dermal filler options, and how she utilizes both in her practice. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank oAntimicrobial Resistance and Psoriasis Remission
https://practicaldermatology.com/series/the-practical-dermatology-podcast/antimicrobial-resistance-and-psoriasis-remission/39042/Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD, FAAD, joins associate medical editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the threat posed by antimicrobial resistance and play “Two Truths and aBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisDermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privDermwireTV: Pharma Partnership Boosts Spesolimab, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pharma-partnership-boosts-spesolimab-plus-more/36519/In this episode of Dermwire TV, two pharma leaders partner to commercialize SPEVIGO for patients with generalized pustular psoriasis; interest in red light devices is up; and experts take a look at what’s new in psoriasis treatments on the Practical Dermatology Podcast.Evaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/series/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andAI for Patient Education and More
https://practicaldermatology.com/series/c-suite-chats/ai-for-patient-education-and-more/36239/Anastasia Georgievskaya, founder of Haut.AI, discusses the impact of new artificial intelligence tools such as a virtual skincare try-on that shows customers how sunscreen and its ingredients will impact skin over time.